BHVN Biohaven Pharmaceutical Holding Company Ltd.

29.77
-4.26  -13%
Previous Close 34.03
Open 33.28
Price To Book -229
Market Cap 1,735,311,102
Shares 58,290,598
Volume 1,013,895
Short Ratio 10.42
Av. Daily Volume 1,143,930
Stock charts supplied by TradingView

NewsSee all news

  1. Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy

    NEW HAVEN, Conn., March 31, 2020 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity

  2. Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine

    NEW HAVEN, Conn., March 30, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced positive topline results in its randomized, placebo-controlled pivotal clinical trial

  3. Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA

    NEW HAVEN, Conn., March 23, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or, the "Company") today announced a successful end of Phase 2 clinical and

  4. Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy

    NEW HAVEN, Conn., Mar. 18, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or the "Company"), a biopharmaceutical company focused on the development and

  5. Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment

    Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today welcomed the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 top-line data due 2Q 2020.
TRORILUZOLE
Obsessive compulsive disorder (OCD)
CRL issued July 19, 2019.
Nurtec (riluzole) (BHV-0223)
Amyotrophic lateral sclerosis (ALS)
Phase 3 top-line data met primary endpoint - March 30, 2020.
Rimegepant
Migraine - preventative
FDA Approval announced February 27, 2020.
Rimegepant Zydis ODT
Acute treatment of migraine
Phase 2/3 top-line data due around the end of 2020.
TRORILUZOLE
Alzheimer’s disease
Phase 3 trial did not meet primary endpoint - February 10, 2020.
TRORILUZOLE
Generalized anxiety disorder (GAD)
Phase 3 commencement of enrolment announced July 31, 2019.
Verdiperstat
Multiple system atrophy (MSA)
Phase 3 trial to be initiated mid-2020.
Vazegepant
Acute treatment of migraine
Phase 3 enrolment to be completed 2Q 2020.
TRORILUZOLE
Spinocerebellar Ataxia (SCA)
Phase 2 commencement of enrolment announced July 1, 2019.
Rimegepant
Refractory trigeminal neuralgia

Latest News

  1. Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy

    NEW HAVEN, Conn., March 31, 2020 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity

  2. Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine

    NEW HAVEN, Conn., March 30, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced positive topline results in its randomized, placebo-controlled pivotal clinical trial

  3. Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA

    NEW HAVEN, Conn., March 23, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or, the "Company") today announced a successful end of Phase 2 clinical and

  4. Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy

    NEW HAVEN, Conn., Mar. 18, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or the "Company"), a biopharmaceutical company focused on the development and

  5. Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment

    Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today welcomed the

  6. Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment

    SOMERSET, N.J., March 17, 2020 /PRNewswire-PRWeb/ -- Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and

  7. Biohaven Announces Patient Savings Program Where Patients Can Pay as Little as $0 for NURTEC™ ODT (rimegepant 75 mg) for the Acute Treatment of Migraine in Adults

    NEW HAVEN, Conn., March 13, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced a Patient Savings Program for NURTEC™ ODT (rimegepant) that is now available for eligible

  8. Biohaven's NURTEC™ ODT (rimegepant 75mg) is Now Available in U.S. Pharmacies for the Acute Treatment of Migraine in Adults

    NEW HAVEN, Conn., March 12, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company (NYSE:BHVN) today announced that NURTEC™ ODT (rimegepant) is now available by prescription in U.S. pharmacies. The U.S. Food and

  9. Biohaven's NURTEC™ ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults

    NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC™ ODT (rimegepant) for the

  10. Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results And Recent Business Developments

    NEW HAVEN, Conn., Feb. 25, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN, the ", Company", )), a biopharmaceutical company with a portfolio of innovative, late-stage product

  11. Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board

    NEW HAVEN, Conn., Feb. 14, 2020 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of

  12. Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List

    NEW HAVEN, Conn., Feb. 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced that Clarivate Analytics plc (NYSE:CCC, CCC.WS)), a global leader in providing trusted insights and

  13. Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint

    NEW HAVEN, Conn., Feb. 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today reported negative topline results from its Phase 3 clinical trial evaluating troriluzole compared to placebo

  14. Kleo Pharmaceuticals Receives IND Authorization to Proceed from FDA for its Multiple Myeloma Therapeutic

    NEW HAVEN, Conn., Feb. 6, 2020 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of

  15. Biohaven Appoints Michael Heffernan To Board Of Directors

    NEW HAVEN, Conn., Jan. 31, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced the appointment of Michael Heffernan to its Board of Directors ("Board").

  16. Biohaven Announces Pricing Of $250 Million Public Offering Of Common Shares

    NEW HAVEN, Conn., Jan. 29, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product candidates targeting

  17. Biohaven Announces Proposed Public Offering Of Common Shares

    NEW HAVEN, Conn., Jan. 28, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product candidates targeting

  18. Biohaven's Verdiperstat Receives FDA May Proceed Letter To Initiate Trial In Amyotrophic Lateral Sclerosis Conducted By The Healey Center For ALS At Mass General

    NEW HAVEN, Conn., Jan. 22, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or the "Company"), a biopharmaceutical company with multiple late-stage neuroscience

  19. Kleo Pharmaceuticals to Present at Biotech Showcase 2020

    NEW HAVEN, Conn., Dec. 18, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of

  20. Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine

    NEW HAVEN, Conn., Dec. 17, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced positive topline results from its randomized, dose ranging, placebo controlled, pivotal Phase 2/3

  21. Biohaven's Troriluzole Successfully Advances Past Interim Futility Analysis In Pivotal Phase 2/3 Alzheimer's Disease Study

    NEW HAVEN, Conn., Dec. 6, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting

  22. Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the U.S. Patent and Trademark Office

    NEW HAVEN, Conn., Dec. 5, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of

  23. Kleo Pharmaceuticals to Present at Piper Jaffray 31st Annual Healthcare Conference

    NEW HAVEN, Conn., Dec. 2, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of

  24. Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM™, a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting

    NEW HAVEN, Conn., Nov. 6, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of

  25. Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole

    NEW HAVEN, Conn., Nov. 5, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting

  26. Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board

    NEW HAVEN, Conn., Nov. 4, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) a clinical-stage biopharmaceutical company provided an update regarding the appointment of Thomas J. Lynch, Jr., MD,

  27. Biohaven Pharmaceuticals Reports Third Quarter 2019 Financial Results And Recent Business Developments

    NEW HAVEN, Conn., Nov. 1, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the "Company"), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage

  28. Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)

    NEW HAVEN, Conn., Sept. 18, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of

  29. Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine

    NEW HAVEN, Conn., Sept. 10, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases,

  30. Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking Session

    NEW HAVEN, Conn., Sept. 9, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) announced today that it presented expanded data and post-hoc analyses from its long term clinical study